Table 3 Multivariate analyses of costs within the first 12 months following allogeneic HSCT for 208 consecutive patients
Variable | Classes | Estimated value | Wald 95% Confidence Limits | P value | |
|---|---|---|---|---|---|
Model 1 included age, sex, number of CMV episodes and survival | |||||
Intercept | 0 | €119,539 | €101,265 | €141,111 | <0.0001 |
Age (years) | < 30 | 1.08 | 0.95 | 1.22 | 0.263 |
30 to 50 | 1.07 | 0.97 | 1.17 | 0.1853 | |
≥ 50 | 1.00 | 1 | 1 | 0 | |
Sex | F | 0.92 | 0.84 | 1.01 | 0.0647 |
M | 1.00 | 1 | 1 | 0 | |
Number of CMV episodes | 0 | 0.80 | 0.70 | 0.91 | 0.0008 |
1 | 0.84 | 0.72 | 0.98 | 0.0253 | |
≥2 | 1.00 | 1 | 1 | 0 | |
Survival status | Dead | 1.08 | 0.99 | 1.18 | 0.0939 |
Alive | 1.00 | 1 | 1 | 0 | |
Model 2 included age, sex, number of CMV episodes, year of transplant and type of graft. Donor/recipient match was excluded because of strong correlation with the type of graft | |||||
Intercept | 0 | €105,461 | €86,051 | €129,250 | <.0001 |
Age (years) | < 30 | 1.07 | 0.97 | 1.18 | 0.1486 |
30 to 50 | 1.06 | 0.93 | 1.20 | 0.3757 | |
≥ 50 | 1.00 | 1.00 | 1.00 | 0 | |
Sex | Females | 0.93 | 0.85 | 1.02 | 0.13 |
Males | 1.00 | 1.00 | 1.00 | . | |
Number of CMV episodes | 0 | 0.78 | 0.68 | 0.90 | 0.0003 |
1 | 0.83 | 0.71 | 0.97 | 0.0201 | |
≥2 | 1.00 | 1.00 | 1.00 | 0 | |
Year of transplant | 2008 | 0.83 | 0.71 | 0.97 | 0.0187 |
2009 | 1.01 | 0.87 | 1.18 | 0.8646 | |
2010 | 1.05 | 0.91 | 1.22 | 0.509 | |
2011 | 1.07 | 0.92 | 1.24 | 0.3775 | |
2012 | 0.97 | 0.83 | 1.13 | 0.6772 | |
2013 | 1.00 | 1.00 | 1.00 | 0 | |
Type of graft | HLA-identical sibling | 1.14 | 0.96 | 1.34 | 0.1242 |
Unrelated donor | 1.13 | 0.96 | 1.32 | 0.1384 | |
Cord Blood Unit | 1.00 | 1.00 | 1.00 | 0 | |